CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00 vs Zio XT ECG Monitoring System

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
VS
by iRhythm Technologies

AI Verdict

Tool A is an advanced 3D cardiac mapping and navigation system for electrophysiologists, designed for real-time guidance during interventional procedures for heart rhythm disorders. In contrast, Tool B is a wearable ECG monitoring system for continuous, long-term ambulatory detection and diagnosis of arrhythmias. While both leverage AI in cardiology, they serve distinct purposes: Tool A for procedural intervention and Tool B for diagnostic monitoring.

Choose CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00 if…

Choose CARTO™ 3 EP Navigation System Software V8.0 if your practice requires a sophisticated, real-time 3D cardiac mapping and navigation solution for complex electrophysiology procedures. This system is ideal for electrophysiologists performing ablations for arrhythmias like AFib and VT, leveraging AI for enhanced signal analysis and precise catheter guidance.

View CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00 →

Choose Zio XT ECG Monitoring System if…

Choose Zio XT ECG Monitoring System if you need a convenient, long-term ambulatory cardiac monitoring solution for patients with suspected intermittent arrhythmias. This wearable biosensor provides up to 14 days of continuous, lead-free ECG data, making it excellent for patient comfort and high compliance in detecting elusive heart rhythm disorders.

View Zio XT ECG Monitoring System →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00 Zio XT ECG Monitoring System
Pricing Unknown Contact for pricing
Deployment On-premise (system with specialized hardware) Cloud-based (AWS EC2 platform), no on-premise hardware required.
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio XT ECG Monitoring System

Tool B offers superior patient usability with its comfortable, water-resistant wearable design and lack of external wires, leading to high patient compliance. For clinicians, its fully cloud-based deployment simplifies workflow by eliminating on-premise hardware requirements.

Clinical Value

CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00

While both tools are FDA-cleared and clinically validated, Tool A directly enhances the precision and safety of complex interventional electrophysiology procedures through real-time 3D mapping and AI-guided analysis. Its impact on immediate treatment outcomes, such as improving ablation success rates, gives it a slight edge in direct clinical impact.

Pricing & Value

Zio XT ECG Monitoring System

Tool B demonstrates greater pricing transparency by publicly disclosing per-patient costs in the UK and proposed Medicare reimbursement rates in the US. In contrast, Tool A's pricing is entirely opaque, requiring direct consultation, which makes it harder for potential buyers to assess value upfront.

Enterprise Readiness

Zio XT ECG Monitoring System

Tool B's fully cloud-based deployment on AWS EC2 requires no on-premise hardware, simplifying IT management, scalability, and maintenance for healthcare enterprises. While Tool A offers cloud storage, its core on-premise system can present greater deployment and integration challenges for large organizations.

Innovation

CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00

Tool A showcases higher innovation by integrating advanced AI and machine learning directly into a real-time, 3D cardiac mapping and navigation system for complex surgical procedures. This real-time, AI-guided intervention in a high-stakes environment represents a more significant technological leap than AI for retrospective analysis of wearable data.

Support & Docs

Tie

Both companies, as established medical device providers, offer comprehensive support and documentation for their respective products. Without specific comparative data on the quality, accessibility, or responsiveness of their support services, it is not possible to definitively declare a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00 Zio XT ECG Monitoring System
Product Name CARTOu2122 3 EP Navigation System Software V8.0 (FG-5400-00 Zio XT ECG Monitoring System
Primary Function AI-powered 3D cardiac mapping and navigation system for electrophysiologists, enhancing diagnosis and treatment of heart rhythm disorders. Wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis.
Company Biosense Webster, Inc. iRhythm Technologies
Categories Cardiology AI, Surgical AI Cardiology AI, Wearables & Remote Monitoring (RPM)
Specialties Cardiology Cardiology, Emergency Medicine, Internal Medicine
Core Technology/Approach AI-powered 3D cardiac mapping and navigation, advanced catheter location, fast anatomical mapping. Wearable single-lead ECG biosensor, continuous ambulatory monitoring, deep-learned AI algorithm for ECG data analysis.

Videos

Demos, reviews, and walkthroughs featuring CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00 and Zio XT ECG Monitoring System.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The CARTOu2122 3 System is an AI-powered 3D cardiac mapping and navigation system for electrophysiologists, enhancing diagnosis and treatment of heart rhythm disorders like AFib and VT during interventional procedures. The Zio XT System offers a wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, primarily for arrhythmia detection and diagnosis in ambulatory patients experiencing symptoms like palpitations, shortness of breath, or dizziness.
The CARTOu2122 3 System uses AI for advanced 3D cardiac mapping, enhanced signal analysis through the CARTO ELEVATEu2122 Module, and automated 3D left atrial anatomy creation with the CARTOSOUNDu2122 FAM Module. The Zio XT System employs an FDA-cleared deep-learned AI algorithm for analyzing ECG data to accurately detect and diagnose arrhythmias, with data curated and verified by qualified cardiac technicians.
The CARTOu2122 3 System is utilized during catheter-based electrophysiological procedures in a lab setting. The Zio XT System provides a non-invasive, wearable single-lead ECG biosensor that patients can wear for up to 14 days, designed for comfort with no external leads or wires and a water-resistant design for normal daily activities.
Pricing for the complete CARTOu2122 3 EP Navigation System Software V8.0 is not publicly available and typically requires direct consultation with Biosense Webster sales representatives. For the Zio XT System, the cost of monitoring in the UK is u00a3310 per patient, and proposed US Medicare rates for the service range approximately from $229-$260.35.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.